Lates News

During the "Fourteenth Five-Year Plan" period, China will comprehensively deepen the reform of drug and medical device regulation to promote the high-quality development of the pharmaceutical industry, with the national drug random inspection pass rate stable at above 99.4%. Yang Sheng, Deputy Director of the National Medical Products Administration, stated that the country supports companies in conducting global simultaneous clinical trials to shorten the global market entry cycle of drugs. It also supports foreign-invested enterprises in introducing original drugs, biologics, and high-end medical equipment for production within the country. Expanding the scope of export sales certificates for pharmaceuticals and medical devices will provide strong support for the internationalization of Chinese pharmaceuticals. Efforts are being accelerated to establish three sub-centers in the Beijing-Tianjin-Hebei, Central China, and Southwest regions. The implementation of the Scientific Action Plan for Drug Regulation aims to accelerate the development of new tools, standards, and methods for regulation.